Expression of constitutively active guanylate cyclase in cardiomyocytes inhibits the hypertrophic effects of isoproterenol and aortic constriction on mouse hearts.
about
Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiencySildenafil citrate increases myocardial cGMP content in rat heart, decreases its hypertrophic response to isoproterenol and decreases myocardial leak of creatine kinase and troponin TCardiac hypertrophy in transgenic rats expressing a dominant-negative mutant of the natriuretic peptide receptor B.Role of Ca2+/calmodulin-stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy.KMUP-1 attenuates isoprenaline-induced cardiac hypertrophy in rats through NO/cGMP/PKG and ERK1/2/calcineurin A pathwaysMembrane sealant Poloxamer P188 protects against isoproterenol induced cardiomyopathy in dystrophin deficient mice.Regulatable atrial natriuretic peptide gene therapy for hypertension.Atrial natriuretic peptide promotes cardiomyocyte survival by cGMP-dependent nuclear accumulation of zyxin and Akt.Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload.Protein kinase G I and heart failure: Shifting focus from vascular unloading to direct myocardial antiremodeling effects.Cyclic nucleotide phosphodiesterase PDE1C1 in human cardiac myocytes.Microarray identifies extensive downregulation of noncollagen extracellular matrix and profibrotic growth factor genes in chronic isolated mitral regurgitation in the dogThe functional genomics of guanylyl cyclase/natriuretic peptide receptor-A: perspectives and paradigmsRegulation of cardiac angiotensin-converting enzyme and angiotensin AT1 receptor gene expression in Npr1 gene-disrupted micemiR-34a modulates angiotensin II-induced myocardial hypertrophy by direct inhibition of ATG9A expression and autophagic activityNitric oxide-cyclic GMP signaling in stem cell differentiationMicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy?Guanylyl cyclase / atrial natriuretic peptide receptor-A: role in the pathophysiology of cardiovascular regulation.Cardioprotective actions of cyclic GMP: lessons from genetic animal models.Regression of copper-deficient heart hypertrophy: reduction in the size of hypertrophic cardiomyocytes.Inhibitors of cyclic nucleotide phosphodiesterase 3 and 5 as therapeutic agents in heart failure.Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes.Retinoic acid and sodium butyrate suppress the cardiac expression of hypertrophic markers and proinflammatory mediators in Npr1 gene-disrupted haplotype mice.Pressure-overload magnitude-dependence of the anti-hypertrophic efficacy of PDE5A inhibition.Emerging Roles of Natriuretic Peptides and their Receptors in Pathophysiology of Hypertension and Cardiovascular RegulationEnhanced activation of pro-inflammatory cytokines in mice lacking natriuretic peptide receptor-A.Constitutive cyclic GMP accumulation in Arabidopsis thaliana compromises systemic acquired resistance induced by an avirulent pathogen by modulating local signals.Genetically altered mutant mouse models of guanylyl cyclase/natriuretic peptide receptor-A exhibit the cardiac expression of proinflammatory mediators in a gene-dose-dependent manner.Cyclic GMP signaling in cardiomyocytes modulates fatty acid trafficking and prevents triglyceride accumulationRole of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target.Treatment for pulmonary arterial hypertension-associated right ventricular dysfunction.Angiotensin II down-regulates natriuretic peptide receptor-A expression and guanylyl cyclase activity in H9c2 (2-1) cardiac myoblast cells: Role of ROS and NF-κB.Molecular pathways underlying cardiac remodeling during pathophysiological stimulation.Myocardial effects of PDE5 inhibition: more function with less mass.Divergence of hypertrophic growth and fetal gene profile: the influence of beta-blockers.Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy.Involvement of the NF-kappa B/matrix metalloproteinase pathway in cardiac fibrosis of mice lacking guanylyl cyclase/natriuretic peptide receptor A.Heme arginate suppresses cardiac lesions and hypertrophy in deoxycorticosterone acetate-salt hypertension.Isoforms of cyclic nucleotide phosphodiesterase PDE3 and their contribution to cAMP hydrolytic activity in subcellular fractions of human myocardium.Mouse strain differences in metabolic fluxes and function of ex vivo working hearts.
P2860
Q24655371-53BF2563-6D13-4DB2-863B-41922559F67DQ24805251-A667E77C-3B3D-4A59-B2B7-A03867729186Q28569799-4EDC9E17-EE01-4B3B-98F6-6A8FCE62F2A7Q33577131-CE7CFE47-C8B4-472F-B8E1-73C87C7C600BQ33730630-2E414B4F-F3F4-4950-B0C2-EF5398127020Q33901556-79113F95-A861-41BB-83B0-379856868AABQ34048214-1165A0B5-F421-45A4-8515-D33829A14481Q34048466-B3E04519-4A08-4B71-95A1-70001E670663Q34300912-3FA721EF-347A-4221-B21A-CF4112CA1629Q34421211-97C242E7-F34E-46AC-BBED-F196B337F679Q34668034-43595B50-D3FA-4412-A2E3-7A0AF45AE4A7Q34973841-8EFAEC04-B18E-438B-9EB2-2A8DFEA98ED4Q34990330-045FE48B-703E-4591-93A7-565E54B8910EQ35050007-2A364150-3ACC-4A67-B336-4A95F2FF0772Q35146756-0A4BCCA9-4E6C-4127-A1FE-6750A10ABE65Q35596709-F7ADB8AF-732D-4F41-8CEC-3879AA44AFF8Q35855552-83DDA18A-7D28-4F35-A7F1-74ECD1F79FB7Q35936915-E5711C2C-1BB9-4468-AF11-6DBFBCC3D0F7Q36164755-E5E9E820-864F-49C6-878F-31B59B622541Q36280926-20D91C7A-BA6B-4394-AA5D-622E8A7D1241Q36512551-BCED5234-EED2-4575-BFBE-C88F51668E72Q37012737-F24D4A9F-73D0-4186-A3A9-AF2A8B6E92BCQ37139674-A5528E36-AAFF-411A-99EF-054F6B48041CQ37245076-E6359AEB-9D08-42FE-A55E-51086CA3760CQ37336602-0BFB1B92-CA37-489C-B6FE-066F36F0CA7AQ37345377-A502E6C1-C100-40AB-B729-1FA86337A38AQ37393910-DC7FEF46-1071-46FD-9DD3-1ADA9BD04E97Q37594085-E4712E8D-3B37-49D1-B3AD-5920AD6873ECQ37632822-6972BE8D-58E8-447F-B54A-44A3D1164891Q38134311-2F176C55-ADD6-49D4-8C0E-9E3A8D1BFAFAQ38235602-F8A4FBF8-E1D5-4CC0-99B5-EA8F31E4D626Q38848847-785E601E-A008-4980-B406-7C725B1141BDQ41855920-F3283D47-18C6-4C47-AA3A-3FDD1B0A1C0CQ42090791-CAF4235D-9BAB-4401-8226-59020D4E3669Q42370598-723607F3-ECD6-477E-B7BA-3F3E1C9373D5Q45235067-1405F134-CD6F-44BA-9A9B-FBD612959D99Q45264888-08401677-DFEB-41CB-B558-86EB0386C007Q46017501-2B801C9B-06F3-4748-A65A-4B7A3806A757Q46711233-84B8BD1D-4D45-4414-AC77-88AB84609B18Q46733241-1186ADBA-5BFB-4DC1-8250-07D25B7F9835
P2860
Expression of constitutively active guanylate cyclase in cardiomyocytes inhibits the hypertrophic effects of isoproterenol and aortic constriction on mouse hearts.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Expression of constitutively a ...... constriction on mouse hearts.
@en
Expression of constitutively a ...... constriction on mouse hearts.
@nl
type
label
Expression of constitutively a ...... constriction on mouse hearts.
@en
Expression of constitutively a ...... constriction on mouse hearts.
@nl
prefLabel
Expression of constitutively a ...... constriction on mouse hearts.
@en
Expression of constitutively a ...... constriction on mouse hearts.
@nl
P2093
P2860
P356
P1476
Expression of constitutively a ...... c constriction on mouse hearts
@en
P2093
Ahmad Zahabi
Nadia Fortin
Sylvie Picard
Timothy L Reudelhuber
P2860
P304
47694-47699
P356
10.1074/JBC.M309661200
P407
P577
2003-09-18T00:00:00Z